
    
      A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination with
      Intramuscular (IM) Fulvestrant to Patients with Estrogen Receptor Positive (ER+) Advanced,
      Metastatic Breast Cancer.
    
  